On this page
How should hepatic metabolism and interaction reports be written?
Separate substrate, inhibition and induction questions. Describe the human-derived test system, conditions, controls and actual findings, then explain any model translating them into potential clinical interactions. Keep measured effects, predictions and proposed clinical actions distinct; the same assay result does not answer every interaction question.
Before you begin
Human hepatic-tissue metabolism and interaction evidence in 5.3.2.2. In-vivo clinical interaction studies and other biomaterial systems have separate placement decisions.
What you will prepare: A report that connects experimental methods and controls to the supported enzyme or interaction conclusion.
Separate substrate, inhibition and induction questions
State whether the experiment identifies metabolic pathways, evaluates the investigational drug as a substrate, or examines its potential to inhibit or induce enzymes. Collect the protocol, human-tissue characterization, reagents and controls, concentration/exposure rationale, assay evidence and calculation records. These experiments answer related questions but are not interchangeable reports.
M4E places hepatic-tissue metabolism and metabolic interaction reports in 5.3.2.2. M12 provides current harmonized guidance for enzyme- and transporter-mediated interaction assessment. Confirm its relevance to the product and mechanism; therapeutic-protein interactions may need a different scientific framework.
Explain the experimental result and translation separately
Describe the tissue system, donors or preparation, incubation conditions, test concentrations, controls and analytical approach sufficiently to understand the experiment. Show how material viability, nonspecific binding, solubility or other assay limitations were assessed where relevant. Report deviations and their effect on the tested mechanism.
Then explain the calculation or model that translates the experimental finding into a potential clinical interaction. Identify exposure inputs, assumptions and uncertainty. Distinguish an observed in-vitro effect from a predicted clinical effect and from a recommendation for a clinical study. Use M12's applicable mechanism-specific framework with scientific review instead of lifting a cutoff from another assay.
Challenge an apparently reassuring negative result
Fictional exercise: an induction experiment shows little change in the target response, but the positive control also failed to respond. The author should report the assay-performance problem and request its scientific disposition. It is not evidence that the drug lacks induction potential.
Before handoff, trace each conclusion to the relevant experiment, control and report version. Reconcile the values used by the clinical DDI plan or model with those in the final laboratory report. If the result remains uncertain, identify the missing evidence and decision owner rather than writing an unqualified “no interaction.” Cross-reference the laboratory report from clinical-pharmacology summaries without duplicating conflicting versions.
Trace the mechanism from laboratory result to clinical interpretation
Build a separate evidence path for each mechanism rather than ending the report with one undifferentiated DDI label.
| Step | Identify | Check before advancing |
|---|---|---|
| Experimental question | Substrate, inhibition or induction role | The endpoint addresses the stated mechanism |
| Laboratory result | System, conditions, controls and uncertainty | The experiment supports an interpretable result |
| Translation | Model, input concentrations and assumptions | Laboratory and clinical quantities are not silently interchanged |
| Clinical implication | Supported interpretation and unresolved questions | Prediction is distinguished from observed clinical evidence |
Review exercise: the final laboratory report changes an input used in an interaction prediction. Ask the modeling owner to regenerate or reassess the prediction and document the effect. Updating the laboratory table while keeping an old model conclusion breaks the evidence path.
Link the experimental result to the relevant clinical DDI report when one exists. If there is disagreement, explain differences in conditions and evidence rather than omitting the less reassuring result from the clinical pharmacology summary.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Are enzyme inhibition and induction interchangeable findings?
No. They concern different interaction mechanisms and require their own experimental and interpretive context. State which mechanism was evaluated, with the relevant controls and limitations. Evidence addressing one mechanism does not establish a negative result for the other.
Can a negative test with a failed positive control establish no interaction?
It cannot be treated as an uncomplicated negative finding. Describe the control-performance problem and obtain the scientist’s assessment of interpretability. The report should preserve that limitation rather than allowing the intended assay design to stand in for demonstrated assay performance.
Does an in-vitro interaction prediction equal an observed clinical interaction?
No. A prediction depends on the experimental evidence, translation model and assumptions. Identify those separately from a clinical study result. M12 provides mechanism-specific assessment principles; the report should not convert a prediction into measured human evidence or automatic management advice.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Guidance
FDA M12: Drug Interaction Studies ↗August 2024 final. Section V on clinical DDI reporting; appendices on in-vitro enzyme and transporter evaluations. Reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.3.2.2. A heading identifies placement, not mandatory applicability.